HOME >> BIOLOGY >> NEWS
Abgenix reports positive clinical data with ABX-IL8 in Psoriasis

Improvement Seen with Multiple Parameters of Disease Measurement

FREMONT, Calif., November 30, 1999 - Abgenix, Inc. (Nasdaq: ABGX) today reported top level results of its Phase I/II clinical trial with ABX-IL8, a fully human antibody developed with the company's XenoMouse™ technology. Additional details will be presented at the Psoriasis: from Gene to Clinic meeting in London on December 2,1999. The multi-center, placebo controlled trial involved 45 patients with moderate to severe psoriasis. Abgenix reported that ABX-IL8 was safe and well tolerated at all dose levels tested and that a dose-dependent improvement was seen in multiple measures of disease. These efficacy measures included psoriasis area severity index (PASI), total body surface area (BSA), Physician's Global Assessment (PGA), and plaque photographs. The company also indicated that it plans to initiate a Phase II clinical trial in psoriasis during the first half of 2000. Other inflammatory disease indications including rheumatoid arthritis continue to be evaluated.

PASI analysis is a widely accepted measure of drug response in psoriasis patients. Fifty-eight percent (58%) of the patients who received ABX-IL8 1.0 mg/kg and 3.0 mg/kg, administered once every three weeks for four consecutive doses, achieved a >25% improvement, and 21% of patients achieved a >50% improvement in PASI score. This compared favorably to patients receiving 0.3 mg/kg ABX-IL8 (20% of patients achieved a >25% improvement and 0% a >50% improvement) and to patients receiving placebo (0% of patients with improvement of >25%). BSA and PGA measures and plaque photographs also showed dose dependent improvement.

"The Phase I/II trial of ABX-IL8 was primarily designed to demonstrate safety so it is a nice surprise to see such encouraging results on efficacy parameters," stated R. Scott Greer, president and CEO of Abgenix. "We will be optimizing the dose and regimen of ABX-IL8
'"/>

Contact: Kurt Leutzinger, Abgenix
510-608-6575
Porter Novelli
30-Nov-1999


Page: 1 2 3

Related biology news :

1. Abgenix to become sole owner of Xenomouse fully human antibody technology
2. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs
3. Abgenix initiates phase III clinical trial of graft versus host disease therapy
4. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody therapeutics
5. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune disease and cancer
6. Abgenix Reports Encouraging Preclinical Results With ABX-EGF In Cancer Research
7. APP reports Abraxane(TM) is active in breast cancer patients who failed taxol or taxotere
8. Scientists question reports of massive ant supercolonies in California and Europe
9. Survey reports fall in stem cell transplants for breast cancer
10. VaxGen reports Phase I clinical trial results of anthrax vaccine candidate
11. Immerge reports PERVs most infectious to human cells not part of germ-line DNA of mini-swine

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... , June 27, 2016 Research and Markets ... America 2016-2020" report to their offering. ... North America to grow at a CAGR of 12.28% ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
Breaking Biology Technology:
Cached News: